• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺表面活性剂液晶纳米结构对呼吸药物传递的影响。

The influence of lung surfactant liquid crystalline nanostructures on respiratory drug delivery.

机构信息

New Zealand's National School of Pharmacy, University of Otago, P.O. Box 56, Dunedin 9054, New Zealand.

Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia.

出版信息

Int J Pharm. 2016 Dec 5;514(2):465-474. doi: 10.1016/j.ijpharm.2016.06.029. Epub 2016 Jun 16.

DOI:10.1016/j.ijpharm.2016.06.029
PMID:27321111
Abstract

The respiratory route increasingly has been used for both local and systemic drug delivery. Although drug is absorbed rapidly after respiratory delivery, the role of lung surfactant in drug delivery is not well understood. The human lung contains only around 15mL of surface lining fluid spread over ∼100m surface. The fluid contains lung surfactant at a concentration of 8-24mg/kg/body weight; the lung surfactant which is lipo-protein in nature can form different liquid crystalline nanostructures. After a brief overview of the anatomy of respiratory system, the review has focused on the current understanding of lung surface lining fluid, lung surfactants and their composition and possible self-assembled nanostructures. The role of lung surfactant in drug delivery and drug dissolution has been briefly considered. Lung surfactant may form different liquid crystalline phases which can have an active role in drug delivery. The hypotheses developed in this review focuses on the potential roles of surface epithelial fluid containing liquid crystalline nanostructures in defining the dissolution mechanism and rate. The hypotheses also focus an understanding how liquid crystalline nanostructures can be used to control dissolution rate and how the nanostructures might be changed to influence delivery and induce toxicity.

摘要

呼吸道越来越多地被用于局部和全身药物输送。虽然药物在呼吸道给药后会迅速被吸收,但肺表面活性剂在药物输送中的作用尚不清楚。人体肺部仅含有约 15 毫升分布在约 100 平方米表面的表面衬里液。该液体内含有浓度为 8-24mg/kg/体重的肺表面活性剂;肺表面活性剂本质上是脂蛋白,可以形成不同的液晶纳米结构。在简要概述呼吸系统解剖结构后,本综述重点介绍了对肺表面衬里液、肺表面活性剂及其组成和可能的自组装纳米结构的现有认识。简要考虑了肺表面活性剂在药物输送和药物溶解中的作用。肺表面活性剂可能形成不同的液晶相,在药物输送中可能具有积极作用。本综述中提出的假设集中于含有液晶纳米结构的表面上皮液在定义溶解机制和速率方面的潜在作用。这些假设还集中于了解液晶纳米结构如何用于控制溶解速率,以及如何改变纳米结构以影响输送并诱导毒性。

相似文献

1
The influence of lung surfactant liquid crystalline nanostructures on respiratory drug delivery.肺表面活性剂液晶纳米结构对呼吸药物传递的影响。
Int J Pharm. 2016 Dec 5;514(2):465-474. doi: 10.1016/j.ijpharm.2016.06.029. Epub 2016 Jun 16.
2
Barrier or carrier? Pulmonary surfactant and drug delivery.屏障还是载体?肺表面活性剂与药物递送。
Eur J Pharm Biopharm. 2015 Sep;95(Pt A):117-27. doi: 10.1016/j.ejpb.2015.02.014. Epub 2015 Feb 20.
3
Understanding the interfacial properties of nanostructured liquid crystalline materials for surface-specific delivery applications.理解纳米结构液晶材料的界面特性,以实现针对表面的特定传递应用。
Langmuir. 2012 Sep 18;28(37):13485-95. doi: 10.1021/la302435g. Epub 2012 Aug 31.
4
Sandwich organization of non-ionic surfactant liquid crystalline phases as induced by large inorganic K4Nb6O17 nanosheets.由大型无机K4Nb6O17纳米片诱导形成的非离子表面活性剂液晶相的三明治结构。
Chem Commun (Camb). 2016 Jan 28;52(8):1594-7. doi: 10.1039/c5cc08948d. Epub 2015 Dec 11.
5
Solid self-nanoemulsifying drug delivery system (S-SNEDDS) of darunavir for improved dissolution and oral bioavailability: In vitro and in vivo evaluation.达芦那韦固体自纳米乳化药物递送系统(S-SNEDDS)用于改善溶解性能和口服生物利用度:体外和体内评价
Eur J Pharm Sci. 2015 Jul 10;74:1-10. doi: 10.1016/j.ejps.2015.03.024. Epub 2015 Apr 3.
6
Nanostructured liquid crystalline particles as an alternative delivery vehicle for plant agrochemicals.纳米结构液晶颗粒作为植物农用化学品的替代传递载体。
ACS Appl Mater Interfaces. 2013 Mar 13;5(5):1818-26. doi: 10.1021/am303208t. Epub 2013 Mar 4.
7
Tailoring liquid crystalline lipid nanomaterials for controlled release of macromolecules.为控制大分子的释放而定制液晶脂纳米材料。
Int J Pharm. 2015 Nov 10;495(1):241-248. doi: 10.1016/j.ijpharm.2015.08.072. Epub 2015 Aug 28.
8
Role of surfactant in the stability of liquid crystal-based nanocolloids.表面活性剂在基于液晶的纳米胶体稳定性中的作用。
Langmuir. 2009 Feb 17;25(4):2419-26. doi: 10.1021/la802881u.
9
Liquid-crystal-mediated self-assembly at nanodroplet interfaces.液芯介导的纳米液滴界面自组装
Nature. 2012 May 2;485(7396):86-9. doi: 10.1038/nature11084.
10
Cubosomes and hexosomes as versatile platforms for drug delivery.立方液晶纳米粒和六方液晶纳米粒作为药物递送的多功能平台。
Ther Deliv. 2015;6(12):1347-64. doi: 10.4155/tde.15.81.

引用本文的文献

1
Recent Advances in the Polish Research on Polysaccharide-Based Nanoparticles in the Context of Various Administration Routes.波兰在基于多糖的纳米颗粒不同给药途径研究方面的最新进展。
Biomedicines. 2023 Apr 28;11(5):1307. doi: 10.3390/biomedicines11051307.
2
Alveolar macrophages: Achilles' heel of SARS-CoV-2 infection.肺泡巨噬细胞:SARS-CoV-2 感染的阿喀琉斯之踵。
Signal Transduct Target Ther. 2022 Jul 19;7(1):242. doi: 10.1038/s41392-022-01106-8.
3
Inhaled RNA Therapeutics for Obstructive Airway Diseases: Recent Advances and Future Prospects.
用于阻塞性气道疾病的吸入式RNA疗法:最新进展与未来前景
Pharmaceutics. 2021 Jan 28;13(2):177. doi: 10.3390/pharmaceutics13020177.
4
Pulmonary route of administration is instrumental in developing therapeutic interventions against respiratory diseases.肺部给药途径有助于开发针对呼吸系统疾病的治疗干预措施。
Saudi Pharm J. 2020 Dec;28(12):1655-1665. doi: 10.1016/j.jsps.2020.10.012. Epub 2020 Nov 4.
5
Design and development of a biorelevant simulated human lung fluid.一种具有生物相关性的模拟人肺液的设计与开发。
J Drug Deliv Sci Technol. 2018 Oct;47:485-491. doi: 10.1016/j.jddst.2018.08.006.
6
Intrapulmonary Pharmacokinetics of Laninamivir, a Neuraminidase Inhibitor, after a Single Nebulized Administration of Laninamivir Octanoate in Healthy Japanese Subjects.健康日本受试者单次吸入洛那米韦辛酸酯后肺内药代动力学的研究。
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01722-17. Print 2018 Jan.
7
A Biocompatible Synthetic Lung Fluid Based on Human Respiratory Tract Lining Fluid Composition.基于人体呼吸道衬液成分的生物相容性合成肺液。
Pharm Res. 2017 Dec;34(12):2454-2465. doi: 10.1007/s11095-017-2169-4. Epub 2017 May 30.